Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1Genitourinary 1

Conditions

Carcinoma, Hepatocellular 46Colorectal Neoplasms 33Stomach Neoplasms 31Esophageal Squamous Cell Carcinoma 27Esophageal Neoplasms 14Rectal Neoplasms 12Cholangiocarcinoma 11Colonic Neoplasms 9Pancreatic Neoplasms 7Neoplasm Metastasis 6Sarcoma 5Carcinoma, Non-Small-Cell Lung 5Locally Advanced Rectal Cancer 4Biliary Tract Neoplasms 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Melanoma 3Liver Neoplasms 3Carcinoma, Renal Cell 3Carcinoma 3Adenocarcinoma Of Esophagus 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Mesothelioma 2Lung Neoplasms 2HER2-positive Gastric Cancer 2Endometrial Neoplasms 2Digestive System Neoplasms 2

Interventions

Gemcitabine 40Cisplatin 24Capecitabine 21Fluorouracil 19Oxaliplatin 17Leucovorin 14pembrolizumab 9Irinotecan 8Radiotherapy 7Erlotinib Hydrochloride 7durvalumab 6Sorafenib 4Photochemotherapy 4Magnetic Resonance Spectroscopy 4Carboplatin 4trametinib 3Trastuzumab 3Radiofrequency Ablation 3Long-Term Synaptic Depression 3Interleukin-12 Subunit p35 3Filgrastim 3Drug Therapy 3Dihematoporphyrin Ether 3Dexamethasone 3Cholangiopancreatography, Endoscopic Retrograde 3Chemotherapy, Adjuvant 3trifluridine tipiracil drug combination 2tivozanib 2tislelizumab 2spartalizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × tislelizumab × Gastrointestinal × Clear all
NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT04666688 2025-02-12

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

PureTech

Phase 1/2 Completed
44 enrolled
GastrointestinalGenitourinaryHead & Neck

Bile Duct Neoplasms, Carcinoma, Transitional Cell, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡